Marex Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Marex Group’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$741K	–	1140
2026 Q1	$741K	Buy	50,000 +25,200	+102%	+$368K	﹤0.01%	517
2025 Q4	$396K	Sell	24,800 -65,200	-72%	-$924K	﹤0.01%	629
2025 Q3	$995K	Sell	90,000 -45,000	-33%	-$492K	0.01%	358
2025 Q2	$1.14M	Sell	135,000 -165,000	-55%	-$1.32M	0.01%	276
2025 Q1	$2.41M	Buy	300,000 +10,000	+3%	+$81K	0.05%	161
2024 Q4	$2.6M	Sell	290,000 -200,000	-41%	-$1.63M	0.04%	143
2024 Q3	$3.59M	Buy	490,000 +190,000	+63%	+$1.18M	0.08%	107
2024 Q2	$1.71M	Hold	300,000	–	–	0.05%	172
2024 Q1	$1.5M	Sell	300,000 -55,000	-15%	-$373K	0.05%	152
2023 Q4	$3.19M	Buy	+355,000	New	+$2.92M	0.13%	122

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's AUPH Position: Q2 2026 in Review

Marex Group sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 50,000 shares — an estimated $741K sold.

Marex Group first reported a position in AUPH in Q4 2023 and held it in 10 quarters. The position peaked at $3.59M in Q3 2024. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Marex Group reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marex Group sold 50,000 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $741K.
Marex Group first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Marex Group's Aurinia Pharmaceuticals position peaked at $3.59M in Q3 2024.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.